As­traZeneca's Imfinzi, Lyn­parza com­bo ap­proved in EU for cer­tain en­dome­tri­al can­cer pa­tients

Two of As­traZeneca’s top can­cer treat­ments have been ap­proved in com­bi­na­tion to treat a sub­group of en­dome­tri­al can­cer pa­tients in the Eu­ro­pean Union, the drug­mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.